Latest Breaking News On - ஒப்பந்தம் தர்க்கம் - Page 1 : comparemela.com

The deal is expected to add a third high-growth commercial franchise for Jazz. Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW s industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities, said Bruce Cozadd, CEO of Jazz. GW Pharma s lead product, plant-derived Epidiolex oral solution, is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex. This product has also been approved, in Europe under the tradename Epidiolex in patients two years of age and older for the adjunctive treatment of seizures associated with LGS and Dravet syndrome in conjunction with clobazam.

Bruce cozaddJazz pharmaceuticalsHigh courtGw pharmaceuticalsBofa securitiesAttention biotech investorsMark your calendar for februaryIdeal logicLennox gastaut syndromeDravet syndromeTuberous sclerosisஜாஸ் மருந்துகள்உயர் நீதிமன்றம்க்வ் மருந்துகள்போஃபா பத்திரங்கள்கவனம் பயோடெக் முதலீட்டாளர்கள்